Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform

Oppenheimer analyst Jay Olson upgraded Dyne Therapeutics (NASDAQ: DYN) from Perform to Outperform with a price target of $40.00 (from $11.00).

For an analyst ratings summary and ratings history on Dyne Therapeutics click here. For more ratings news on Dyne Therapeutics click here.

Shares of Dyne Therapeutics closed at $18.45 yesterday.

You May Also Be Interested In

• Seaport Global Securities Upgrades Analog Devices (ADI) to Buy, 'appears to be entering the sweet part of the cycle'
• Elanco Animal Health (ELAN) Reiterated at Buy by Stifel as Rebate Activity Accelerates
• Ramaco Resources names new CAO and general counsel